Inflammatory bowel disease and colitis: new concepts from the bench and the clinic
暂无分享,去创建一个
[1] S. Fine. Adalimumab for the treatment of fistulas in patients with Crohn's disease. , 2011, Inflammatory bowel diseases.
[2] R. Xavier,et al. Virus-Plus-Susceptibility Gene Interaction Determines Crohn's Disease Gene Atg16L1 Phenotypes in Intestine , 2010, Cell.
[3] J. Gisbert,et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy , 2010, Gut.
[4] L. Peyrin-Biroulet,et al. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France , 2010, Inflammatory bowel diseases.
[5] J. Galmiche,et al. Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn's disease. , 2010, Gastroenterology.
[6] W. Sandborn,et al. Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.
[7] P. Rutgeerts,et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.
[8] P. Rutgeerts,et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. , 2010, Gastroenterology.
[9] D. Philpott,et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry , 2010, Nature Immunology.
[10] D. Jewell,et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation , 2010, Nature Medicine.
[11] Johan Van Limbergen,et al. Common variants at five new loci associated with early-onset inflammatory bowel disease , 2009, Nature Genetics.
[12] F. Carrat,et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study , 2009, The Lancet.
[13] P. Rutgeerts,et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.
[14] Y. Yazdanpanah,et al. The European (ECCO) Consensus on infection in IBD: what does it change for the clinician? , 2009, Gut.
[15] G Van Assche,et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis , 2009, Gut.
[16] H. Sokol,et al. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine , 2009, Alimentary pharmacology & therapeutics.
[17] C. Lees,et al. The safety profile of anti‐tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient‐years follow‐up , 2009, Alimentary pharmacology & therapeutics.
[18] J. Gisbert,et al. Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain: A Nationwide, Multicenter Study , 2009, The American Journal of Gastroenterology.
[19] H. Tilg,et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.
[20] P. Rutgeerts,et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study , 2007, Gut.
[21] P. Rutgeerts,et al. Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.
[22] M. Kamm,et al. Infliximab for the treatment of fistulas in patients with Crohn'S disease. , 1999, Gastroenterology.
[23] P. Rutgeerts,et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.